{
    "data": [
        {
            "id": "69037446ecb8a70001458beb",
            "title": "Microsoft On Path To $5 Trillion Market Cap: Analyst Says &#39;AI Revolution Hits Next Gear&#39;",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Microsoft Corporation </strong>(NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MSFT\" target=\"_blank\">MSFT</a>) highlighted AI and cloud growth during its <a href=\"https://www.benzinga.com/markets/earnings/25/10/48512244/microsoft-q1-earnings-highlights-ai-cloud-power-double-beat-strong-start-to-the-fiscal-year\" target=\"_blank\">first-quarter financial results.</a> Here's what analysts are saying about the quarter and what comes next.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>MSFT shares are experiencing downward pressure. <a href=\"https://www.benzinga.com/quote/MSFT\" rel=\"noreferrer noopener\" target=\"_blank\">Review the technical setup here.</a></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>The Microsoft Analysts:</strong> </p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>Wedbush analyst Dan Ives maintained an Outperform rating on Microsoft with a price target of $625.</li>\n<li>Goldman Sachs analyst Kash Rangan reiterated a Buy rating on Microsoft with a price target of $630.</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Wedbush on MSFT:</strong> Strength in Microsoft's Azure was \"front and center\" for the company in the first quarter, Ives said in an investor note.</p><!--/$--><!--$--><p class=\"block core-block\">\"AI Revolution hits next gear,\" Ives said.</p><!--/$--><!--$--><p class=\"block core-block\">Ives said Microsoft is continuing to capitalize on growth opportunities in the cloud segment.</p><!--/$--><!--$--><p class=\"block core-block\">The analyst highlights that Microsoft has more customers building AI apps and agents on its Azure infrastructure.</p><!--/$--><!--$--><p class=\"block core-block\">Ives highlights Microsoft's commercial remaining performance obligations up 51% year-over-year to $392 billion.</p><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--><!--$--><p class=\"block core-block\">\"MSFT fully committed to the AI buildout as the company looks to increase its AI capacity by 80% y/y with ~2x its data center footprint over the next two years.\"</p><!--/$--><!--$--><p class=\"block core-block\">Ives said the next stop for Microsoft could be joining Nvidia in the $5 trillion market capitalization club, with strong forward guidance for fiscal 2026.</p><!--/$--><!--$--><p class=\"block core-block\">\"It remains clear that FY26 remains the true inflection year of AI growth for Microsoft.\"  </p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Read Also: <a href=\"https://www.benzinga.com/markets/tech/25/10/48518415/microsoft-cfo-amy-hood-says-cloud-revenue-figures-could-be-higher-but-azure-is-short-on-capacity-as-ai-demand-soars\" target=\"_blank\">Microsoft CFO Amy Hood Says Cloud Revenue Figures ‘Could Be Higher,’ But Azure Is ‘Short On Capacity’ As AI Demand Soars</a></strong></p><!--/$--><!--$--><p class=\"block core-block\"><strong>Goldman Sachs on MSFT:</strong> The technology giant is \"compounding growth at scale\" and reporting solid margins, Rangan said in a new investor note.</p><!--/$--><!--$--><p class=\"block core-block\">With shares down after-hours on Wednesday, Rangan said the weakness in the stock could be related to fiscal 2026 guidance, higher CapEx, and higher equity ownership expenses in OpenAI.</p><!--/$--><!--$--><p class=\"block core-block\">\"We think these issues are relatively near-term and tactical, and we remain constructive on the stock,\" Rangan said.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The analyst highlighted Microsoft Azure growth of 39% year-over-year, constant currency, in the quarter, which was one of the highest growth rates of Hyperscalers.</p><!--/$--><!--$--><p class=\"block core-block\">Rangan said Microsoft has done a great job of scaling operating margins even with higher CapEx spending recently.</p><!--/$--><!--$--><p class=\"block core-block\">For the company's OpenAI investment that will be adjusted based on non-GAAP earnings per share, Rangan said investors should still consider the value of owning around 27% of OpenAI moving forward.</p><!--/$--><!--$--><p class=\"block core-block\">\"We believe Microsoft is one of the most compelling investment opportunities in the technology industry and across sectors.\"</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The analyst said Microsoft will be able to capitalize on long-term trends like cloud consumption, digital transformation and generative AI.</p><!--/$--><!--$--><p class=\"block core-block\">\"We see potential for sustained long-term growth.\"</p><!--/$--><!--$--><p class=\"block core-block\"><strong>MSFT Price Action:</strong> Microsoft stock is down 2.2% to $529.76 on Thursday versus a 52-week trading range of $344.79 to $555.45. Microsoft stock is up 26.6% year-to-date in 2025.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48530114\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/news/25/10/48494920/magnificent-seven-market-cap-today-china-japan-gdp-nvidia-5-trillion-ai-jensen-huang-mags-etf\" target=\"_blank\">Magnificent 7 Market Cap Tops $22 Trillion – And Nvidia Just Got Bigger Than Japan</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image created using artificial intelligence via Midjourney.</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/microsoft-mid.png",
            "link": "https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48530114/microsoft-on-path-to-5-trillion-market-cap-analyst-says-ai-revolution-hits-next-gear",
            "pub_date": "2025-10-30 22:20:57",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69037684ecb8a70001458d0d",
            "title": "Here&#39;s How Much You Would Have Made Owning Ensign Group Stock In The Last 15 Years",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Ensign Group (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ENSG\" target=\"_blank\">ENSG</a>) has outperformed the market over the past 15 years by 9.26% on an annualized basis producing an average annual return of 21.4%. Currently, Ensign Group has a market capitalization of $10.56 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $1000 In ENSG:</strong> If an investor had bought $1000 of ENSG stock 15 years ago, it would be worth <strong>$19,027.95</strong> today based on a price of $183.02 for ENSG at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">Ensign Group's Performance Over Last 15 Years</h3><!--/$--><!--$--><div class=\"sc-feVKPA LhjAx core-image flex items-center justify-center\"><span style=\"background:none;border:0;box-sizing:border-box;display:inline-block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:relative;max-width:100%\"><span style=\"background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;padding:0;width:initial;max-width:100%\"><img alt=\"\" aria-hidden=\"true\" src=\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMTUwMCIgaGVpZ2h0PSI4MDAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyIgdmVyc2lvbj0iMS4xIi8+\" style=\"background:none;border:0;display:block;height:initial;margin:0;max-width:100%;opacity:1;padding:0;width:initial\"/></span><img alt=\"\" decoding=\"async\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/><noscript><img alt=\"\" decoding=\"async\" fetchpriority=\"low\" loading=\"lazy\" sizes=\"(max-width: 800px) 1500px, (min-width: 800px) 1500px\" src=\"https://www.benzinga.com/files/images/story/2025/1761834629_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840\" srcset=\"https://www.benzinga.com/files/images/story/2025/1761834629_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920 1x, https://www.benzinga.com/files/images/story/2025/1761834629_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840 2x\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/></noscript></span></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/25/10/48530390/heres-how-much-you-would-have-made-owning-ensign-group-stock-in-the-last-15-years",
            "pub_date": "2025-10-30 22:30:32",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903709becb8a70001458808",
            "title": "Mounjaro And Zepbound Power Eli Lilly&#39;s 54% Revenue Jump In Q3, Hikes 2025 Forecast",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Eli Lilly and Co.</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/LLY\" target=\"_blank\">LLY</a>) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><em>LLY stock is gaining positive traction. <a href=\"https://www.benzinga.com/quote/LLY\" rel=\"noreferrer noopener\" target=\"_blank\">See the full story here</a></em></strong></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The U.S. <a href=\"https://www.benzinga.com/topic/weight-loss\" rel=\"noreferrer noopener\" target=\"_blank\">weight loss drug giant</a> reported quarterly revenue of $17.60 billion, up 54% year over year, beating the <a href=\"https://www.benzinga.com/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $16.02 billion</a>, driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices.</p><!--/$--><!--$--><p class=\"block core-block\">Key Products revenue grew to $11.98 billion in Q3 2025, led by Mounjaro and Zepbound.</p><!--/$--><!--$--><p class=\"block core-block\">The company reported an adjusted earnings per share of $7.02, a sharp jump from $1.18 a year ago, beating the consensus of $5.70.</p><!--/$--><!--$--><p class=\"block core-block\"><strong><em>Also Read: <a href=\"https://www.benzinga.com/news/health-care/25/10/48507071/eli-lilly-advances-ai-and-access-supercomputer-with-nvidia-zepbound-via-walmart\" rel=\"noreferrer noopener\" target=\"_blank\">Eli Lilly Advances AI And Access: Supercomputer With NVIDIA, Zepbound Via Walmart</a></em></strong></p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Weightloss Drugs</h2><!--/$--><!--$--><p class=\"block core-block\">Mounjaro’s revenue increased 109% for the quarter to $6.52 billion. U.S. revenue was $3.55 billion, an increase of 49%, reflecting strong demand, partially offset by lower realized prices.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue outside the U.S. increased to $2.97 billion compared with $728.0 million in Q3 2024, primarily <a href=\"https://www.benzinga.com/pressreleases/25/10/n48521986/lilly-reports-third-quarter-2025-financial-results-highlights-r-d-pipeline-momentum-and-raises-202\" rel=\"noreferrer noopener\" target=\"_blank\">driven by volume growth</a>.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">U.S. Zepbound revenue increased 184% to $3.57 billion, primarily driven by increased demand, partially offset by lower realized prices.</p><!--/$--><!--$--><p class=\"block core-block\">Verzenio (a breast cancer drug) revenue increased 7% to $1.47 billion, driven by volume growth.</p><!--/$--><!--$--><p class=\"block core-block\">Gross profit increased 57% to $14.59 billion. Gross margin was 82.9%, an increase of 1.9 percentage points, driven by a favorable product mix, partially offset by lower realized prices.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Outlook</strong></h2><!--/$--><!--$--><p class=\"block core-block\">Eli Lilly raised fiscal year 2025 sales guidance from $60 billion-$62 billion to $63 billion-$63.5 billion versus the consensus of $61.65 billion.</p><!--/$--><!--$--><p class=\"block core-block\">The obesity drug maker raised 2025 adjusted earnings guidance <a href=\"https://www.benzinga.com/markets/earnings/25/08/46960692/eli-lillys-closely-watched-obesity-pill-orforglipron-shows-around-12-weight-loss-but-trails-novo-nordisk\" rel=\"noreferrer noopener\" target=\"_blank\">from $21.75-$23.00</a> to $23-$23.70 versus the consensus of $22.18.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">On Wednesday, Eli Lilly announced a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico.</p><!--/$--><!--$--><p class=\"block core-block\">Construction on the expanded oral solid medicine product manufacturing facility is estimated to begin in 2026, with plans to start producing medicine <a href=\"https://www.benzinga.com/pressreleases/25/10/n48496871/lilly-announces-more-than-1-2-billion-investment-in-puerto-rico-facility-to-boost-oral-medicine-ma\" rel=\"noreferrer noopener\" target=\"_blank\">by the end of 2028</a>. </p><!--/$--><!--$--><p class=\"block core-block\">The new investment will integrate advanced technologies and expand production capacity to support the portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology, and immunology.</p><!--/$--><!--$--><p class=\"block core-block\">The enhanced facility will be among those that will manufacture orforglipron, Lilly’s first oral weight loss drug.</p><!--/$--><!--$--><p class=\"block core-block\">Lilly estimates the project will generate up to 1,000 construction jobs and 100 additional high-tech manufacturing positions.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>LLY Price Action:</strong> Eli Lilly shares were up 2.29% at $832.16 at the time of publication on Thursday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><em><a href=\"https://www.benzinga.com/node/48526401\" rel=\"noreferrer noopener\" target=\"_blank\">Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges</a></em></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by M7kk via Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48529099\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Weight-Loss-Injection-Pen---Mounjaro-Inj.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48529099/mounjaro-and-zepbound-power-eli-lillys-54-revenue-jump-in-q3-hikes-2025-forecast",
            "pub_date": "2025-10-30 22:05:19",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690373ececb8a70001458ba6",
            "title": "Cleveland-Cliffs (CLF) Stock Is Sliding Thursday: What&#39;s Going On?",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Shares of <strong>Cleveland-Cliffs Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CLF\" target=\"_blank\">CLF</a>) are trading lower Thursday after the company announced the pricing of a public offering of 75 million common shares. Here’s what investors <a href=\"https://www.benzinga.com/pressreleases/25/10/b48522176/cleveland-cliffs-inc-prices-public-offering-of-75-000-000-common-shares\" target=\"_blank\">need to know</a>.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>CLF shares are retreating from recent levels. <a href=\"https://www.benzinga.com/quote/CLF\" rel=\"noreferrer noopener\" target=\"_blank\">See the trading setup here.</a></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>What To Know:</strong> The steelmaker expects to raise gross proceeds of approximately $964 million, implying a price of about $12.85 per share. CLF plans to use the funds to repay borrowings under its credit facility. This action increases the number of shares outstanding, a dilutive move that is putting pressure on the stock price.</p><!--/$--><!--$--><p class=\"block core-block\">The offering follows a recent surge in investor interest after CLF revealed it is exploring opportunities in the rare earth minerals sector. On its third-quarter call, CEO <strong>Lourenco Goncalves</strong> <a href=\"https://www.benzinga.com/trading-ideas/movers/25/10/48317211/cleveland-cliffs-explores-rare-earths-stock-soars\" target=\"_blank\">highlighted</a> the company is assessing ore and tailings sites in Minnesota and Michigan for rare earth potential. </p><!--/$--><!--$--><p class=\"block core-block\">This long-term strategic initiative aims to create a domestic supply chain for critical materials, but Thursday’s focus remains on the near-term impact of the stock dilution.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Benzinga Edge Rankings:</strong> <a href=\"http://benzinga.grsm.io/register174\" target=\"_blank\">Benzinga Edge</a> Rankings highlight the stock’s strong Momentum score of 81.66, despite a low Growth score of 10.15.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><strong>CLF Price Action:</strong> Cleveland-Cliffs shares were down 12.82% at $12.28 at the time of publication on Thursday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Read Also: <a href=\"https://www.benzinga.com/markets/commodities/25/10/48525772/trump-hints-at-potential-very-large-scale-alaska-oil-and-gas-deal-with-china\" target=\"_blank\">Trump Hints At Potential ‘Very Large Scale’ Alaska Oil And Gas Deal With China</a></strong></p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">How To Buy CLF Stock</h2><!--/$--><!--$--><p class=\"block core-block\">By now you're likely curious about how to participate in the market for Cleveland-Cliffs – be it to purchase shares, or even attempt to bet against the company.</p><!--/$--><!--$--><p class=\"block core-block\">Buying shares is typically done through a brokerage account. You can find a list of <a href=\"https://www.benzinga.com/money/best-stock-trading-platforms\" target=\"_blank\">possible trading platforms here.</a> Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a <a href=\"https://www.benzinga.com/money/how-to-short-a-stock\" target=\"_blank\">stock can be found at this resource.</a>  Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48530048\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Konskie--Poland---February-24--2024-Clev.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/25/10/48530048/cleveland-cliffs-clf-stock-is-sliding-thursday-whats-going-on",
            "pub_date": "2025-10-30 22:19:27",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690373fbecb8a70001458baf",
            "title": "Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\">Shares of <strong>Cardinal Health, Inc.</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CAH\" target=\"_blank\">CAH</a>) rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results and raised its FY25 adjusted EPS <a href=\"https://www.benzinga.com/quote/CAH/earnings\" target=\"_blank\">guidance above estimates</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Cardinal Health reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.18 per share. The company reported quarterly sales of $64.009 billion which beat the analyst consensus estimate of $59.197 billion.</p><!--/$--><!--$--><p class=\"block core-block\">Cardinal Health shares jumped 17.5% to $193.26 on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\">Here are some other big stocks recording gains in today’s session.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Guardant Health, Inc</strong>. (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/GH\" target=\"_blank\">GH</a>) shares jumped 29.3% to $93.45 after the company reported better-than-expected third-quarter financial results and raised its FY25 sales guidance above estimates.</li>\n<li><strong>Emergent BioSolutions Inc</strong>. (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/EBS\" target=\"_blank\">EBS</a>) gained 29% to $12.11 after the company reported better-than-expected quarterly financial results and raised its FY25 sales guidance.</li>\n<li><strong>Glaukos Corporation</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/GKOS\" target=\"_blank\">GKOS</a>) surged 28.7% to $99.20 after the company reported better-than-expected quarterly financial results and raised its FY25 sales guidance above estimates.</li>\n<li><strong>C.H. Robinson Worldwide, Inc</strong>. (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CHRW\" target=\"_blank\">CHRW</a>) shares rose 21.3% to $156.66 after the company reported better-than-expected third-quarter adjusted EPS results.</li>\n<li><strong>Viavi Solutions Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/VIAV\" target=\"_blank\">VIAV</a>) gained 21.1% to $16.93 after the company reported first-quarter results above estimates and issued second-quarter guidance above expectations.</li>\n<li><strong>Perimeter Solutions, Inc. </strong>(NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/PRM\" target=\"_blank\">PRM</a>) rose 21% to $25.96 following upbeat earnings.</li>\n<li><strong>FormFactor, Inc. </strong>(NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FORM\" target=\"_blank\">FORM</a>) gained 21% to $57.71 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates.</li>\n<li><strong>Metsera, Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MTSR\" target=\"_blank\">MTSR</a>) rose 20.9% to $63.15 after Novo Nordisk confirmed it submitted an unsolicited proposal to acquire the company.</li>\n<li><strong>Immunovant, Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/IMVT\" target=\"_blank\">IMVT</a>) gained 20% to $26.00.</li>\n<li><strong>Bausch Health Companies Inc</strong>. (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/BHC\" target=\"_blank\">BHC</a>) rose 15% to $6.79 after the company reported better-than-expected third-quarter financial results and raised its FY25 sales guidance.</li>\n<li><strong>Insmed Incorporated</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/INSM\" target=\"_blank\">INSM</a>) gained 11.8% to $186.35 after the company raised its FY2025 global ARIKAYCE sales guidance.</li>\n<li><strong>XPO, Inc.</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/XPO\" target=\"_blank\">XPO</a>) rose 11.3% to $138.82 following strong quarterly earnings.</li>\n<li><strong>WESCO International, Inc</strong>. (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/WCC\" target=\"_blank\">WCC</a>) rose 10% to $251.41 after posting upbeat quarterly results.</li>\n<li><strong>Calix, Inc</strong>. (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CALX\" target=\"_blank\">CALX</a>) gained 9.3% to $68.00 after the company reported better-than-expected third-quarter financial results and issued current-quarter guidance above estimates.</li>\n<li><strong>CommScope Holding Company, Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/COMM\" target=\"_blank\">COMM</a>) shares rose 8.1% to $17.02 after the company reported quarterly results above estimates.</li>\n<li><strong>Huntington Ingalls Industries, Inc</strong>. (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/HII\" target=\"_blank\">HII</a>) gained 7.3% to $320.12 after the company reported third-quarter results above estimates.</li>\n<li><strong>Extreme Networks, Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/EXTR\" target=\"_blank\">EXTR</a>) jumped 7.2% to $19.31 following upbeat quarterly earnings.</li>\n<li><strong>Fox Corporation</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FOX\" target=\"_blank\">FOX</a>) gained 6.4% to $57.83 after the company reported better-than-expected quarterly financial results and announced a $1.5 billion accelerated share buyback transaction.</li>\n<li><strong>Alphabet Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/GOOG\" target=\"_blank\">GOOG</a>) rose 5.2% to $289.57 following upbeat quarterly results.</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Read This Next: </strong></p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48519346/top-wall-street-forecasters-revamp-amazon-expectations-ahead-of-q3-earnings\" target=\"_blank\">Top Wall Street Forecasters Revamp Amazon Expectations Ahead Of Q3 Earnings</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\">Photo via Shutterstock</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48530058\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Cardinal-Health-Logo-Sign-On-The-Buildin.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/25/10/48530058/cardinal-health-posts-upbeat-q1-results-joins-guardant-health-glaukos-c-h-robinson-and-other-big-stocks-moving-higher-on-thursday",
            "pub_date": "2025-10-30 22:19:43",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}